文献速递眼底病与葡萄膜炎

高体重指数与非感染性葡萄膜炎患者阿达木单抗血清水平降低及疾病活动度升高相关

High Body Mass Index is Associated with Lower Adalimumab Serum Levels and Higher Disease Activity in Noninfectious Uveitis.
PubMed 文献 · Am J Ophthalmol · 2024-12-17

这项单中心横断面临床研究纳入80例接受阿达木单抗治疗的非感染性葡萄膜炎患者,发现体重指数(BMI)与阿达木单抗血清谷浓度呈显著负相关(r=-0.408,P=.007),BMI是治疗应答的显著预测因子(P=.017),BMI阈值26.4以上应答概率显著降低,51.2%的患者为无应答者且均可检测到抗阿达木单抗抗体。

要点

  • BMI与阿达木单抗血清谷浓度呈显著负相关(r=-0.408,P=.007)。
  • BMI是治疗应答的显著预测因子(P=.017),阈值26.4以上应答概率显著降低。
  • 51.2%的患者为无应答者,所有无应答者均可检测到抗阿达木单抗抗体。

核心结论

  • 较高的BMI与非感染性葡萄膜炎患者阿达木单抗谷浓度降低及治疗效果下降相关。
  • BMI阈值26.4可能作为调整阿达木单抗治疗的临床标志物,提示对BMI升高的患者需要个体化给药策略。

研究设计与样本

  • 横断面临床研究,单中心。
  • 研究人群为80例接受阿达木单抗治疗的非感染性葡萄膜炎患者。
  • 测量阿达木单抗血清谷浓度和抗阿达木单抗抗体水平,在治疗开始时计算BMI并将患者分为正常体重、超重、肥胖和病态肥胖组。
  • 使用Pearson相关、卡方检验和逻辑回归分析BMI、阿达木单抗水平与临床应答之间的相关性。

主要发现

  • 较高的BMI与较低的阿达木单抗血清水平和降低的临床应答可能性相关。
  • BMI与阿达木单抗水平之间存在显著负相关(r=-0.408,P=.007)。
  • 逻辑回归确定BMI是治疗应答的显著预测因子(P=.017)。
  • 确定BMI阈值26.4,高于此阈值时阳性应答概率显著降低。
  • 51.2%的患者为无应答者,所有无应答者均可检测到抗阿达木单抗抗体。

关键数值与推荐

  • BMI与阿达木单抗水平的Pearson相关系数r=-0.408,P=.007。
  • 逻辑回归中BMI预测治疗应答的P=.017。
  • BMI阈值26.4,高于此值阳性应答概率显著降低。
  • 无应答者比例为51.2%,所有无应答者均可检测到抗阿达木单抗抗体。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adalimumab, a TNF-alpha inhibitor, is the only FDA-approved biologic for non-infectious uveitis (NIU). However, treatment responses vary, potentially due to interindividual pharmacokinetic differences influenced by body mass index (BMI). This study aimed to evaluate the impact of BMI on adalimumab serum trough levels and therapeutic efficacy in patients with NIU. DESIGN: Cross-sectional, clinical study. METHODS: Setting: Single-center study. - Study Population: 80 patients with NIU treated with Adalimumab - Observation Procedure: Adalimumab serum trough levels and anti-Adalimumab antibody (AAA) levels were measured. BMI was calculated at treatment initiation, and patients were categorized into normal weight, overweight, obese, and morbidly obese groups. - Main Outcome Measures: The correlation between BMI, adalimumab levels, and clinical response was analyzed using Pearson correlation, chi-square tests, and logistic regression. RESULTS: Higher BMI was associated with lower adalimumab serum levels and a reduced likelihood of clinical response. A significant negative correlation was found between BMI and adalimumab levels (r = -0.408, P = .007). Logistic regression identified BMI as a significant predictor of treatment response (P = .017). A BMI threshold of 26.4 was identified, above which the probability of a positive response significantly decreased. Additionally, 51.2% of patients were non-responders, all of whom demonstrated detectable AAA. CONCLUSIONS: Higher BMI is associated with lower adalimumab trough levels and reduced treatment efficacy in NIU patients. A BMI threshold of 26.4 may serve as a clinical marker for tailoring adalimumab therapy, highlighting the need for personalized dosing strategies in patients with elevated BMI.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pichi F, AlAli SH, Jimenez YP, et al. High Body Mass Index is Associated with Lower Adalimumab Serum Levels and Higher Disease Activity in Noninfectious Uveitis. Am J Ophthalmol. 2024. PMID: 39701506. doi:10.1016/j.ajo.2024.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。